Hybrid And Complex Opportunities Remain At The Heart Of Endo’s Strategy

 
• By Dean Rudge

Endo continues to see value in 505(b)(2) sterile injectables and complex generics, while “swift, tough decisions” on its more commoditised US retail generics are helping put the company ahead of its competitors.

Chess
Injectables are key to Endo's strategy • Source: Shutterstock

More from Strategy

More from Business